BillionToOne, Inc.

Healthcare / Diagnostics & Research

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Performance

--
Today 0.00 (0.00%)
BLLN

Metrics

Market Cap4.7B
Latest Price$91.88
Previous Close$97.50
Volume779K
52 Week High$150.44
52 Week Low$61.96
52 Week Change-3.01%
Average Volume614K
Revenue437M
EPS0.92
P/E Ratio105.978
Forward P/E62.102
Price/Book8.197
Profit Margin0.11%
Operating Margin0.10%
Return on Equity0.13%
Dividend Yield0.00%

Recent News for BLLN